REL-1017
REL-1017-202
Phase 2 small_molecule completed
Quick answer
REL-1017 for Depressive Disorder, Major is a Phase 2 program (small_molecule) at RELMADA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- RELMADA THERAPEUTICS, INC.
- Indication
- Depressive Disorder, Major
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed